Kilitch Drugs (India) Ltd: Share Price Analysis, Intrinsic Value & Fundamentals (2025)

Share Price and Basic Stock Data

Last Updated: March 8, 2025, 1:33 pm

Market Cap	496 Cr.
Current Price	308
High / Low	405/294
Stock P/E	27.7
Book Value	118
Dividend Yield	0.00 %
ROCE	12.6 %
ROE	7.71 %
Face Value	10.0
PEG Ratio	0.72

Stock P/E, Current Price, and Intrinsic Value Over Time

Stock P/E Current Price Intrinsic Value

View Share Price Target for Kilitch Drugs (India) Ltd

Competitors of Kilitch Drugs (India) Ltd

Stock Name ⇩	Market Cap ⇩	Current Price ⇩	High / Low ⇩	Stock P/E ⇩	Book Value ⇩	Dividend Yield ⇩	ROCE ⇩	ROE ⇩	Face Value ⇩
MPS Pharmaa Ltd	6.71 Cr.	3.51	4.33/3.05		0.80	0.00 %	9.15 %	34.9 %	10.0
Gujarat Themis Biosyn Ltd	2,663 Cr.	244	390/192	50.6	20.5	0.27 %	45.0 %	33.8 %	1.00
Gujarat Terce Laboratories Ltd	53.1 Cr.	71.5	94.9/32.1	18.0	11.9	0.00 %	9.72 %	3.44 %	10.0
Gujarat Inject (Kerala) Ltd	38.0 Cr.	26.0	29.0/8.74	38.8	6.64	0.00 %	2.65 %	2.08 %	10.0
Godavari Drugs Ltd	70.4 Cr.	93.5	155/79.0	11.4	55.4	0.00 %	14.4 %	15.5 %	10.0
Industry Average	17,255.37 Cr	1,081.84		42.42	185.80	0.37%	16.00%	16.32%	6.27

All Competitor Stocks of Kilitch Drugs (India) Ltd

Quarterly Result

Metric	Dec 2021	Mar 2022	Jun 2022	Sep 2022	Dec 2022	Mar 2023	Jun 2023	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024
Sales	34.43	36.61	33.45	30.70	29.97	45.48	36.56	41.20	31.79	44.82	33.45	47.47	56.17
Expenses	33.66	31.57	30.03	26.75	25.99	39.26	30.38	32.58	29.51	37.74	31.79	41.37	47.44
Operating Profit	0.77	5.04	3.42	3.95	3.98	6.22	6.18	8.62	2.28	7.08	1.66	6.10	8.73
OPM %	2.24%	13.77%	10.22%	12.87%	13.28%	13.68%	16.90%	20.92%	7.17%	15.80%	4.96%	12.85%	15.54%
Other Income	1.31	0.38	0.97	0.24	0.69	1.02	0.56	0.49	2.96	0.47	2.57	5.16	1.73
Interest	0.24	0.71	0.67	1.75	1.29	1.21	1.50	1.51	1.60	1.32	1.73	0.31	1.40
Depreciation	0.20	1.13	0.82	0.89	0.93	0.91	0.71	0.82	0.81	0.93	0.85	0.61	0.81
Profit before tax	1.64	3.58	2.90	1.55	2.45	5.12	4.53	6.78	2.83	5.30	1.65	10.34	8.25
Tax %	62.80%	36.03%	40.00%	-25.16%	30.61%	43.16%	32.67%	24.93%	38.16%	30.57%	93.33%	16.73%	32.00%
Net Profit	0.61	2.30	1.74	1.94	1.71	2.90	3.06	5.09	1.74	3.68	0.11	8.61	5.61
EPS in Rs	0.72	1.86	1.34	1.56	1.52	2.28	2.16	2.95	1.81	2.23	0.83	5.36	3.71

Last Updated: February 28, 2025, 6:53 pm

Below is a detailed analysis of the quarterly data for Kilitch Drugs (India) Ltd based on the most recent figures (Dec 2024) and their trends compared to the previous period:

For Sales, as of Dec 2024, the value is ₹56.17 Cr.. The value appears strong and on an upward trend. It has increased from 47.47 Cr. (Sep 2024) to ₹56.17 Cr., marking an increase of ₹8.70 Cr..
For Expenses, as of Dec 2024, the value is ₹47.44 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 41.37 Cr. (Sep 2024) to ₹47.44 Cr., marking an increase of ₹6.07 Cr..
For Operating Profit, as of Dec 2024, the value is ₹8.73 Cr.. The value appears strong and on an upward trend. It has increased from 6.10 Cr. (Sep 2024) to ₹8.73 Cr., marking an increase of ₹2.63 Cr..
For OPM %, as of Dec 2024, the value is 15.54%. The value appears strong and on an upward trend. It has increased from 12.85% (Sep 2024) to 15.54%, marking an increase of 2.69%.
For Other Income, as of Dec 2024, the value is ₹1.73 Cr.. The value appears to be declining and may need further review. It has decreased from 5.16 Cr. (Sep 2024) to ₹1.73 Cr., marking a decrease of 3.43 Cr..
For Interest, as of Dec 2024, the value is ₹1.40 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 0.31 Cr. (Sep 2024) to ₹1.40 Cr., marking an increase of ₹1.09 Cr..
For Depreciation, as of Dec 2024, the value is ₹0.81 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 0.61 Cr. (Sep 2024) to ₹0.81 Cr., marking an increase of ₹0.20 Cr..
For Profit before tax, as of Dec 2024, the value is ₹8.25 Cr.. The value appears to be declining and may need further review. It has decreased from 10.34 Cr. (Sep 2024) to ₹8.25 Cr., marking a decrease of 2.09 Cr..
For Tax %, as of Dec 2024, the value is 32.00%. The value appears to be increasing, which may not be favorable. It has increased from 16.73% (Sep 2024) to 32.00%, marking an increase of 15.27%.
For Net Profit, as of Dec 2024, the value is ₹5.61 Cr.. The value appears to be declining and may need further review. It has decreased from 8.61 Cr. (Sep 2024) to ₹5.61 Cr., marking a decrease of 3.00 Cr..
For EPS in Rs, as of Dec 2024, the value is 3.71. The value appears to be declining and may need further review. It has decreased from ₹5.36 (Sep 2024) to 3.71, marking a decrease of ₹1.65.

Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.

Quarterly Chart

Profit & Loss - Annual Report

Last Updated: March 6, 2025, 3:44 pm

Metric	Mar 2011	Mar 2012	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	TTM
Sales	146	108	19	21	27	51	82	53	68	114	140	154	182
Expenses	124	95	21	25	28	45	75	53	63	104	122	130	158
Operating Profit	22	13	-2	-4	-1	6	7	0	5	10	18	24	24
OPM %	15%	12%	-9%	-19%	-2%	11%	9%	1%	8%	9%	13%	16%	13%
Other Income	0	92	3	2	1	3	4	4	3	3	3	4	10
Interest	4	3	0	0	0	0	1	1	1	1	5	6	5
Depreciation	6	5	2	10	10	2	2	2	2	2	4	3	3
Profit before tax	13	97	-1	-12	-9	6	9	2	5	10	12	19	26
Tax %	20%	22%	-70%	-4%	-5%	16%	55%	48%	27%	35%	31%	30%
Net Profit	10	76	-0	-11	-9	5	4	1	4	6	8	14	18
EPS in Rs	7.93	57.67	-0.22	-8.46	-6.72	3.75	2.49	0.54	2.37	4.73	6.71	9.08	12.13
Dividend Payout %	13%	52%	0%	0%	0%	13%	20%	0%	0%	0%	0%	0%

Profit & Loss Yearly Chart

YoY Net Profit Growth

Year	2011-2012	2016-2017	2017-2018	2018-2019	2019-2020	2020-2021	2021-2022	2022-2023	2023-2024
YoY Net Profit Growth (%)	660.00%	18.18%	155.56%	-20.00%	-75.00%	300.00%	50.00%	33.33%	75.00%
Change in YoY Net Profit Growth (%)	0.00%	-641.82%	137.37%	-175.56%	-55.00%	375.00%	-250.00%	-16.67%	41.67%

Kilitch Drugs (India) Ltd has shown an inconsistent trend in YoY Net Profit Growth (%) in the last 9 years from 2011-2012 to 2023-2024.

No data available for the compounded sales growth chart.

Balance Sheet

Last Updated: December 14, 2024, 3:18 pm

Month	Mar 2011	Mar 2012	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Sep 2024
Equity Capital	13	13	13	13	13	14	15	15	15	16	16	16	16
Reserves	71	101	107	95	88	98	106	103	112	124	136	160	173
Borrowings	16	9	0	0	1	1	9	13	15	20	22	32	32
Other Liabilities	53	54	7	8	11	15	13	12	61	50	46	32	38
Total Liabilities	153	177	127	117	113	128	144	143	203	210	220	240	259
Fixed Assets	42	9	9	42	33	33	32	32	30	65	64	62	63
CWIP	43	0	0	0	1	3	20	30	65	3	4	6	22
Investments	0	138	72	49	53	56	53	52	60	71	62	72	76
Other Assets	68	30	46	25	26	35	38	30	47	71	90	100	99
Total Assets	153	177	127	117	113	128	144	143	203	210	220	240	259

Below is a detailed analysis of the balance sheet data for Kilitch Drugs (India) Ltd based on the most recent figures (Sep 2024) and their trends compared to the previous period:

For Equity Capital, as of Sep 2024, the value is ₹16.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2024) which recorded ₹16.00 Cr..
For Reserves, as of Sep 2024, the value is ₹173.00 Cr.. The value appears strong and on an upward trend. It has increased from ₹160.00 Cr. (Mar 2024) to ₹173.00 Cr., marking an increase of 13.00 Cr..
For Borrowings, as of Sep 2024, the value is ₹32.00 Cr.. The value remains steady. Additionally, since Reserves exceed Borrowings, this is considered a positive sign. There is no change compared to the previous period (Mar 2024) which recorded ₹32.00 Cr..
For Other Liabilities, as of Sep 2024, the value is ₹38.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from ₹32.00 Cr. (Mar 2024) to ₹38.00 Cr., marking an increase of 6.00 Cr..
For Total Liabilities, as of Sep 2024, the value is ₹259.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from ₹240.00 Cr. (Mar 2024) to ₹259.00 Cr., marking an increase of 19.00 Cr..
For Fixed Assets, as of Sep 2024, the value is ₹63.00 Cr.. The value appears strong and on an upward trend. It has increased from ₹62.00 Cr. (Mar 2024) to ₹63.00 Cr., marking an increase of 1.00 Cr..
For CWIP, as of Sep 2024, the value is ₹22.00 Cr.. The value appears strong and on an upward trend. It has increased from ₹6.00 Cr. (Mar 2024) to ₹22.00 Cr., marking an increase of 16.00 Cr..
For Investments, as of Sep 2024, the value is ₹76.00 Cr.. The value appears strong and on an upward trend. It has increased from ₹72.00 Cr. (Mar 2024) to ₹76.00 Cr., marking an increase of 4.00 Cr..
For Other Assets, as of Sep 2024, the value is ₹99.00 Cr.. The value appears to be declining and may need further review. It has decreased from ₹100.00 Cr. (Mar 2024) to ₹99.00 Cr., marking a decrease of 1.00 Cr..
For Total Assets, as of Sep 2024, the value is ₹259.00 Cr.. The value appears strong and on an upward trend. It has increased from ₹240.00 Cr. (Mar 2024) to ₹259.00 Cr., marking an increase of 19.00 Cr..

Notably, the Reserves (₹173.00 Cr.) exceed the Borrowings (32.00 Cr.), indicating a solid financial buffer.

Overall, while many items appear to show a positive trend, any significant downward movement or items where Borrowings exceed Reserves warrant further investigation.

Reserves and Borrowings Chart

No data available for this post.

Free Cash Flow

Month	Mar 2011	Mar 2012	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024
Free Cash Flow	6.00	4.00	-2.00	-4.00	-2.00	5.00	-2.00	-13.00	-10.00	-10.00	-4.00	-8.00

Free Cash Flow = Income Generated from Operational Activities - Borrowings - Capital Work in Progress (CWIP)

Consistent positive free cash flow is crucial for businesses as it indicates their ability to generate cash from their core operations. It provides financial flexibility, allowing companies to invest in growth opportunities, pay dividends to shareholders, reduce debt, and weather economic downturns more effectively.

Free Cash Flow Chart

Financial Efficiency Indicators

Month	Mar 2011	Mar 2012	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024
Debtor Days	97	51	243	286	196	148	86	109	122	132	142	149
Inventory Days	62	12	124	110	84	39	36	70	35	28	10	18
Days Payable	37	19	124	154	184	108	33	89	525	239	200	118
Cash Conversion Cycle	121	44	243	241	96	79	89	89	-367	-79	-48	50
Working Capital Days	19	-114	197	237	124	100	79	108	-144	25	54	105
ROCE %	15%	8%		-10%	-9%	5%	6%	1%	3%	6%	10%	13%

Financial Efficiency Indicators Chart

Share Holding Pattern

Month	Mar 2022	Jun 2022	Sep 2022	Dec 2022	Mar 2023	Jun 2023	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024
Promoters	68.25%	68.25%	68.24%	68.24%	68.24%	68.24%	69.23%	69.23%	69.23%	69.23%	69.23%	69.23%
Public	31.75%	31.75%	31.75%	31.75%	31.75%	31.76%	30.78%	30.76%	30.77%	30.77%	30.77%	30.76%
No. of Shareholders	9,133	9,209	9,380	9,435	9,522	9,573	9,002	9,062	9,525	9,620	9,920	10,139

Shareholding Pattern Chart

No. of Shareholders

This stock is not held by any mutual fund

ROCE Trend

EPS Trend

Key Financial Ratios

Month	Mar 24	Mar 23	Mar 22	Mar 21	Mar 20
FaceValue	10.00	10.00	10.00	10.00	10.00
Basic EPS (Rs.)	9.17	6.71	4.73	2.37	0.55
Diluted EPS (Rs.)	9.17	6.71	4.73	2.37	0.55
Cash EPS (Rs.)	10.52	7.59	5.57	3.71	1.84
Book Value[Excl.RevalReserv]/Share (Rs.)	109.23	96.64	90.03	83.56	78.05
Book Value[Incl.RevalReserv]/Share (Rs.)	109.23	96.64	90.03	83.56	78.05
Revenue From Operations / Share (Rs.)	95.99	89.59	73.31	44.22	34.55
PBDIT / Share (Rs.)	17.80	13.15	8.52	5.07	2.80
PBIT / Share (Rs.)	15.72	10.87	6.94	3.79	1.50
PBT / Share (Rs.)	12.03	7.71	6.17	3.30	1.04
Net Profit / Share (Rs.)	8.44	5.32	3.99	2.43	0.54
NP After MI And SOA / Share (Rs.)	9.08	6.71	4.73	2.37	0.54
PBDIT Margin (%)	18.54	14.67	11.62	11.47	8.10
PBIT Margin (%)	16.37	12.12	9.46	8.57	4.35
PBT Margin (%)	12.53	8.60	8.41	7.47	3.01
Net Profit Margin (%)	8.79	5.93	5.43	5.49	1.57
NP After MI And SOA Margin (%)	9.45	7.48	6.44	5.35	1.57
Return on Networth / Equity (%)	8.28	6.89	5.29	2.88	0.71
Return on Capital Employeed (%)	14.37	11.24	7.69	4.52	1.92
Return On Assets (%)	6.08	4.75	3.51	1.80	0.58
Total Debt / Equity (X)	0.17	0.14	0.14	0.11	0.10
Asset Turnover Ratio (%)	0.67	0.65	0.48	0.41	0.38
Current Ratio (X)	2.27	1.84	1.65	1.10	2.54
Quick Ratio (X)	2.21	1.81	1.57	1.05	2.29
Inventory Turnover Ratio (X)	26.22	21.16	14.04	8.31	7.10
Dividend Payout Ratio (NP) (%)	0.00	0.00	0.00	0.00	110.48
Dividend Payout Ratio (CP) (%)	0.00	0.00	0.00	0.00	32.74
Earning Retention Ratio (%)	0.00	0.00	0.00	0.00	-10.48
Cash Earning Retention Ratio (%)	0.00	0.00	0.00	0.00	67.26
Interest Coverage Ratio (X)	4.83	4.16	11.08	10.42	6.04
Interest Coverage Ratio (Post Tax) (X)	3.29	2.68	6.18	5.99	2.18
Enterprise Value (Cr.)	638.35	218.65	272.89	130.24	137.43
EV / Net Operating Revenue (X)	4.14	1.57	2.39	1.90	2.58
EV / EBITDA (X)	22.29	10.67	20.55	16.57	31.80
MarketCap / Net Operating Revenue (X)	4.06	1.56	2.29	1.83	2.35
Retention Ratios (%)	0.00	0.00	0.00	0.00	-10.48
Price / BV (X)	3.56	1.43	1.88	0.98	1.06
Price / Net Operating Revenue (X)	4.06	1.56	2.29	1.83	2.35
EarningsYield	0.02	0.04	0.02	0.02	0.01

After reviewing the key financial ratios for Kilitch Drugs (India) Ltd, here is a detailed analysis based on the latest available data and recent trends:

For FaceValue, as of Mar 24, the value is 10.00. This value is within the healthy range. There is no change compared to the previous period (Mar 23) which recorded 10.00.
For Basic EPS (Rs.), as of Mar 24, the value is 9.17. This value is within the healthy range. It has increased from 6.71 (Mar 23) to 9.17, marking an increase of 2.46.
For Diluted EPS (Rs.), as of Mar 24, the value is 9.17. This value is within the healthy range. It has increased from 6.71 (Mar 23) to 9.17, marking an increase of 2.46.
For Cash EPS (Rs.), as of Mar 24, the value is 10.52. This value is within the healthy range. It has increased from 7.59 (Mar 23) to 10.52, marking an increase of 2.93.
For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 24, the value is 109.23. It has increased from 96.64 (Mar 23) to 109.23, marking an increase of 12.59.
For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 24, the value is 109.23. It has increased from 96.64 (Mar 23) to 109.23, marking an increase of 12.59.
For Revenue From Operations / Share (Rs.), as of Mar 24, the value is 95.99. It has increased from 89.59 (Mar 23) to 95.99, marking an increase of 6.40.
For PBDIT / Share (Rs.), as of Mar 24, the value is 17.80. This value is within the healthy range. It has increased from 13.15 (Mar 23) to 17.80, marking an increase of 4.65.
For PBIT / Share (Rs.), as of Mar 24, the value is 15.72. This value is within the healthy range. It has increased from 10.87 (Mar 23) to 15.72, marking an increase of 4.85.
For PBT / Share (Rs.), as of Mar 24, the value is 12.03. This value is within the healthy range. It has increased from 7.71 (Mar 23) to 12.03, marking an increase of 4.32.
For Net Profit / Share (Rs.), as of Mar 24, the value is 8.44. This value is within the healthy range. It has increased from 5.32 (Mar 23) to 8.44, marking an increase of 3.12.
For NP After MI And SOA / Share (Rs.), as of Mar 24, the value is 9.08. This value is within the healthy range. It has increased from 6.71 (Mar 23) to 9.08, marking an increase of 2.37.
For PBDIT Margin (%), as of Mar 24, the value is 18.54. This value is within the healthy range. It has increased from 14.67 (Mar 23) to 18.54, marking an increase of 3.87.
For PBIT Margin (%), as of Mar 24, the value is 16.37. This value is within the healthy range. It has increased from 12.12 (Mar 23) to 16.37, marking an increase of 4.25.
For PBT Margin (%), as of Mar 24, the value is 12.53. This value is within the healthy range. It has increased from 8.60 (Mar 23) to 12.53, marking an increase of 3.93.
For Net Profit Margin (%), as of Mar 24, the value is 8.79. This value is within the healthy range. It has increased from 5.93 (Mar 23) to 8.79, marking an increase of 2.86.
For NP After MI And SOA Margin (%), as of Mar 24, the value is 9.45. This value is within the healthy range. It has increased from 7.48 (Mar 23) to 9.45, marking an increase of 1.97.
For Return on Networth / Equity (%), as of Mar 24, the value is 8.28. This value is below the healthy minimum of 15. It has increased from 6.89 (Mar 23) to 8.28, marking an increase of 1.39.
For Return on Capital Employeed (%), as of Mar 24, the value is 14.37. This value is within the healthy range. It has increased from 11.24 (Mar 23) to 14.37, marking an increase of 3.13.
For Return On Assets (%), as of Mar 24, the value is 6.08. This value is within the healthy range. It has increased from 4.75 (Mar 23) to 6.08, marking an increase of 1.33.
For Total Debt / Equity (X), as of Mar 24, the value is 0.17. This value is within the healthy range. It has increased from 0.14 (Mar 23) to 0.17, marking an increase of 0.03.
For Asset Turnover Ratio (%), as of Mar 24, the value is 0.67. It has increased from 0.65 (Mar 23) to 0.67, marking an increase of 0.02.
For Current Ratio (X), as of Mar 24, the value is 2.27. This value is within the healthy range. It has increased from 1.84 (Mar 23) to 2.27, marking an increase of 0.43.
For Quick Ratio (X), as of Mar 24, the value is 2.21. This value exceeds the healthy maximum of 2. It has increased from 1.81 (Mar 23) to 2.21, marking an increase of 0.40.
For Inventory Turnover Ratio (X), as of Mar 24, the value is 26.22. This value exceeds the healthy maximum of 8. It has increased from 21.16 (Mar 23) to 26.22, marking an increase of 5.06.
For Dividend Payout Ratio (NP) (%), as of Mar 24, the value is 0.00. This value is below the healthy minimum of 20. There is no change compared to the previous period (Mar 23) which recorded 0.00.
For Dividend Payout Ratio (CP) (%), as of Mar 24, the value is 0.00. This value is below the healthy minimum of 20. There is no change compared to the previous period (Mar 23) which recorded 0.00.
For Earning Retention Ratio (%), as of Mar 24, the value is 0.00. This value is below the healthy minimum of 40. There is no change compared to the previous period (Mar 23) which recorded 0.00.
For Cash Earning Retention Ratio (%), as of Mar 24, the value is 0.00. This value is below the healthy minimum of 40. There is no change compared to the previous period (Mar 23) which recorded 0.00.
For Interest Coverage Ratio (X), as of Mar 24, the value is 4.83. This value is within the healthy range. It has increased from 4.16 (Mar 23) to 4.83, marking an increase of 0.67.
For Interest Coverage Ratio (Post Tax) (X), as of Mar 24, the value is 3.29. This value is within the healthy range. It has increased from 2.68 (Mar 23) to 3.29, marking an increase of 0.61.
For Enterprise Value (Cr.), as of Mar 24, the value is 638.35. It has increased from 218.65 (Mar 23) to 638.35, marking an increase of 419.70.
For EV / Net Operating Revenue (X), as of Mar 24, the value is 4.14. This value exceeds the healthy maximum of 3. It has increased from 1.57 (Mar 23) to 4.14, marking an increase of 2.57.
For EV / EBITDA (X), as of Mar 24, the value is 22.29. This value exceeds the healthy maximum of 15. It has increased from 10.67 (Mar 23) to 22.29, marking an increase of 11.62.
For MarketCap / Net Operating Revenue (X), as of Mar 24, the value is 4.06. This value exceeds the healthy maximum of 3. It has increased from 1.56 (Mar 23) to 4.06, marking an increase of 2.50.
For Retention Ratios (%), as of Mar 24, the value is 0.00. This value is below the healthy minimum of 30. There is no change compared to the previous period (Mar 23) which recorded 0.00.
For Price / BV (X), as of Mar 24, the value is 3.56. This value exceeds the healthy maximum of 3. It has increased from 1.43 (Mar 23) to 3.56, marking an increase of 2.13.
For Price / Net Operating Revenue (X), as of Mar 24, the value is 4.06. This value exceeds the healthy maximum of 3. It has increased from 1.56 (Mar 23) to 4.06, marking an increase of 2.50.
For EarningsYield, as of Mar 24, the value is 0.02. This value is below the healthy minimum of 5. It has decreased from 0.04 (Mar 23) to 0.02, marking a decrease of 0.02.

Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.

Profitability Ratios (%)

Liquidity Ratios

Liquidity Ratios (%)

Interest Coverage Ratios (%)

Valuation Ratios

Fair Value

Fair Value of Kilitch Drugs (India) Ltd as of March 12, 2025 is: ₹205.64

Calculation basis:

Fair value = P/E Ratio * (Return on Equity / 100) * Book Value * (1 + Dividend Yield / 100)
P/E Ratio (Price-to-Earnings Ratio): Represents the price of the stock relative to its earnings per share. A higher P/E ratio indicates that investors are willing to pay a higher price for the stock.
Return on Equity (ROE): Measures a company's profitability relative to its shareholder equity. It showcases the company's ability to generate profits using the investment made by its shareholders, offering valuable insight into its operational efficiency and financial performance.
Book Value: Represents the net asset value of the company per share. It is calculated as the total assets minus intangible assets and liabilities, divided by the number of outstanding shares.
Dividend Yield: The ratio of the annual dividend per share to the current market price per share. It offers valuable insights into the profitability of an investment through dividends.

This formula allows us to gauge the fair value of the stock by analyzing its fundamental indicators.

As of March 12, 2025, Kilitch Drugs (India) Ltd is Overvalued by 33.23% compared to the current share price 308.00

Intrinsic Value of Kilitch Drugs (India) Ltd as of March 12, 2025 is: 285.06

Calculation basis:

Intrinsic value = P/E Ratio * (Return on Equity / 100) * Book Value * (1 + Dividend Yield / 100) * (1 + EPS CAGR for Last 5 Years)
P/E Ratio (Price-to-Earnings Ratio): Represents the price of the stock relative to its earnings per share. A higher P/E ratio indicates that investors are willing to pay a higher price for the stock.
Return on Equity (ROE): Measures a company's profitability relative to its shareholder equity. It showcases the company's ability to generate profits using the investment made by its shareholders, offering valuable insight into its operational efficiency and financial performance.
Book Value: Represents the net asset value of the company per share. It is calculated as the total assets minus intangible assets and liabilities, divided by the number of outstanding shares.
Dividend Yield: The ratio of the annual dividend per share to the current market price per share. It offers valuable insights into the profitability of an investment through dividends.
EPS CAGR (Compound Annual Growth Rate): Represents the geometric mean growth rate of earnings per share over the last 5 years. It provides insight into the historical growth trajectory of the company's earnings.

This formula allows us to gauge the intrinsic value of the stock by analyzing its fundamental indicators along with EPS growth.

As of March 12, 2025, Kilitch Drugs (India) Ltd is Overvalued by 7.45% compared to the current share price 308.00

Last 5 Year EPS CAGR: 38.62%

*Investments are subject to market risks

Strength and Weakness

Strength	Weakness
The company has higher reserves (113.38 cr) compared to borrowings (13.08 cr), indicating strong financial stability. The company has shown consistent growth in sales (89.62 cr) and profit (13.62 cr) over the years.	The stock has a low average ROCE of 4.00%, which may not be favorable. The stock has a high average Working Capital Days of 65.83, which may not be favorable. The stock has a high average Cash Conversion Cycle of 46.50, which may not be favorable.

Stock Analysis

Considering all of the following key financial indicators, prospective investors are encouraged to conduct thorough research and seek professional guidance before considering any investment in Kilitch Drugs (India) Ltd:
1. Net Profit Margin: 8.79%
  - Net Profit Margin: This metric indicates the percentage of profit a company makes from its total revenue. A higher net profit margin is generally desirable as it reflects better profitability.
2. ROCE: 14.37% (Industry Average ROCE: 16%)
  - ROCE (Return on Capital Employed): ROCE measures a company's profitability and the efficiency with which its capital is employed. A higher ROCE indicates efficient use of capital.
3. ROE%: 8.28% (Industry Average ROE: 16.32%)
  - ROE (Return on Equity): ROE measures a company's profitability relative to shareholders' equity. A higher ROE indicates efficient use of shareholders' funds.
4. Interest Coverage Ratio (Post Tax): 3.29
  - Interest Coverage Ratio: The interest coverage ratio measures a company's ability to cover its interest payments on outstanding debt. A ratio greater than 2 is generally considered healthy as it indicates the company can meet its interest obligations comfortably.
5. Quick Ratio: 2.21
  - Quick Ratio: The quick ratio assesses a company's ability to cover its short-term liabilities with its most liquid assets. A ratio higher than 1 suggests the company can meet its short-term obligations without relying heavily on inventory.
6. Stock P/E: 27.7 (Industry average Stock P/E: 42.42)
  - Stock P/E (Price-to-Earnings) Ratio: The P/E ratio compares a company's current share price to its earnings per share. A lower P/E ratio relative to industry peers or historical values may indicate that the stock is undervalued.
7. Total Debt / Equity: 0.17
  - Total Debt / Equity: This ratio measures a company's financial leverage by comparing its total debt to its total equity. A lower ratio indicates lower financial risk and greater financial stability.
The current analysis is available for review. It's important to conduct thorough research and consider consulting with financial professionals before making any investment decisions.
Stock Rating:

About the Company - Qualitative Analysis

Kilitch Drugs(I) Ltd. is a Public Limited Listed company incorporated on 12/05/1992 and has its registered office in the State of Maharashtra, India. Company's Corporate Identification Number(CIN) is L24239MH1992PLC066718 and registration number is 066718. Currently Company is involved in the business activities of Manufacture of pharmaceuticals, medicinal chemical and botanical products. Company's Total Operating Revenue is Rs. 131.60 Cr. and Equity Capital is Rs. 16.08 Cr. for the Year ended 31/03/2024.

INDUSTRY	ADDRESS	CONTACT
Pharmaceuticals	C-301/2, M.I.D.C., New Mumbai Maharashtra 400705	info@kilitch.com http://www.kilitch.com

Management
Name	Position Held
Mr. Mukund P Mehta	Managing Director
Mr. Bhavin Mukund Mehta	Whole Time Director
Mrs. Mira B Mehta	Whole Time Director
Mr. Hemang J Engineer	Independent Director
Mr. Venkita Subramanian Rajan	Independent Director
Prof. Vasudev Krishna Murti	Independent Director

FAQ

What is the latest intrinsic value of Kilitch Drugs (India) Ltd?

The latest intrinsic value of Kilitch Drugs (India) Ltd as on 12 March 2025 is ₹205.64, which is 33.23% lower than the current market price of 308.00, indicating the stock is overvalued by 33.23%. The intrinsic value of Kilitch Drugs (India) Ltd is calculated using PE ratio method. The stock has a market capitalization of ₹496 Cr. and recorded a high/low of ₹405/294 during the current fiscal year 2024-2025. As of Sep 2024, the company has reserves of ₹173 Cr and total liabilities of ₹259 Cr.

What is the Market Cap of Kilitch Drugs (India) Ltd?

The Market Cap of Kilitch Drugs (India) Ltd is 496 Cr..

What is the current Stock Price of Kilitch Drugs (India) Ltd as on 12 March 2025?

The current stock price of Kilitch Drugs (India) Ltd as on 12 March 2025 is ₹308.

What is the High / Low of Kilitch Drugs (India) Ltd stocks in FY 2024-2025?

In FY 2024-2025, the High / Low of Kilitch Drugs (India) Ltd stocks is ₹405/294.

What is the Stock P/E of Kilitch Drugs (India) Ltd?

The Stock P/E of Kilitch Drugs (India) Ltd is 27.7.

What is the Book Value of Kilitch Drugs (India) Ltd?

The Book Value of Kilitch Drugs (India) Ltd is 118.

What is the Dividend Yield of Kilitch Drugs (India) Ltd?

The Dividend Yield of Kilitch Drugs (India) Ltd is 0.00 %.

What is the ROCE of Kilitch Drugs (India) Ltd?

The ROCE of Kilitch Drugs (India) Ltd is 12.6 %.

What is the ROE of Kilitch Drugs (India) Ltd?

The ROE of Kilitch Drugs (India) Ltd is 7.71 %.

What is the Face Value of Kilitch Drugs (India) Ltd?

The Face Value of Kilitch Drugs (India) Ltd is 10.0.